Paul C. Grint
2016 - Regulus Therapeutics
In 2016, Paul C. Grint earned a total compensation of $2.9M as President & Chief Executive Officer at Regulus Therapeutics, a 43% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $154,500 |
|---|---|
| Option Awards | $2,195,583 |
| Salary | $515,000 |
| Other | $4,551 |
| Total | $2,869,634 |
Grint received $2.2M in option awards, accounting for 77% of the total pay in 2016.
Grint also received $154.5K in non-equity incentive plan, $515K in salary and $4.6K in other compensation.
Rankings
In 2016, Paul C. Grint's compensation ranked 3,353rd out of 14,075 executives tracked by ExecPay. In other words, Grint earned more than 76.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,353 out of 14,075 | 76th |
Division Manufacturing | 1,165 out of 5,486 | 79th |
Major group Chemicals And Allied Products | 349 out of 1,900 | 82nd |
Industry group Drugs | 252 out of 1,543 | 84th |
Industry Pharmaceutical Preparations | 197 out of 1,173 | 83rd |
Source: SEC filing on April 28, 2017.
Grint's colleagues
We found two more compensation records of executives who worked with Paul C. Grint at Regulus Therapeutics in 2016.